Silo Pharma (SILO) Cash from Investing Activities (2018 - 2026)
Silo Pharma (SILO) posted Cash from Investing Activities of -$23563.0 for Q1 2026, up 95.47% sequentially from -$519988.0 in Q4 2025, and down 102.7% YoY from $871381.0 in Q1 2025.
Silo Pharma (SILO) Cash from Investing Activities (2018 - 2026) Analysis & Trends
Silo Pharma has reported Cash from Investing Activities for 9 years, with the latest figure at -$23563.0 in Q1 2026.
- Quarterly Cash from Investing Activities fell 102.7% year-over-year to -$23563.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$250923.0 (down 114.36% YoY) and the FY2025 annual result came in at $644021.0, down 33.86% from the prior year.
- Cash from Investing Activities advanced to -$23563.0 in Q1 2026 per SILO's latest filing, from -$519988.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $4.4 million in Q4 2023 and troughed at -$6.0 million in Q1 2023.
- A 5-year average of -$164411.0 and a median of $20000.0 in 2022 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2023 and 2025: Cash from Investing Activities tumbled 30141.7% in 2023, then soared 792.84% in 2025.
- Over 5 years, Cash from Investing Activities stood at $66707.0 in 2022, then jumped by 6539.34% to $4.4 million in 2023, then sank by 100.85% to -$37659.0 in 2024, then sank by 1280.78% to -$519988.0 in 2025, then surged by 95.47% to -$23563.0 in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$23563.0, -$519988.0, and -$95474.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Silo Pharma | 2.92 Mn | 2.92 Mn | - | 183,439.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 183,439.00 |
| Jun 30, 2026 | 183,439.00 |
| Mar 31, 2026 | -23,563.00 |
| Mar 31, 2026 | -23,563.00 |
| Dec 31, 2025 | -519,988.00 |
| Dec 31, 2025 | -519,988.00 |
| Sep 30, 2025 | -95,474.00 |
| Sep 30, 2025 | -95,474.00 |
| Jun 30, 2025 | 388,102.00 |
| Jun 30, 2025 | 388,102.00 |
| Mar 31, 2025 | 871,381.00 |
| Mar 31, 2025 | 871,381.00 |
| Dec 31, 2024 | -37,659.00 |
| Dec 31, 2024 | -37,659.00 |
| Sep 30, 2024 | -40,432.00 |
| Sep 30, 2024 | -40,432.00 |
| Jun 30, 2024 | 954,272.00 |
| Jun 30, 2024 | 954,272.00 |
| Mar 31, 2024 | 97,596.00 |
| Mar 31, 2024 | 97,596.00 |